Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis

J Hum Genet. 2004;49(9):474-481. doi: 10.1007/s10038-004-0176-x. Epub 2004 Aug 4.

Abstract

Paraoxonase1 (PON1) gene polymorphisms were implicated as risk factors for Parkinson's disease (PD), but the results of case-control studies that investigated these associations were controversial. In order to provide an answer to these contradictory results, a meta-analysis of all available studies relating the PON1-55M/L and PON1-192Q/R polymorphisms to the risk of developing PD was conducted. The racial descent of the populations in these studies was Caucasian and Asian. The meta-analysis revealed that there was an association of the PON1-55M allele and the risk of developing PD relative to the L allele: fixed effects pooled odds ratio (OR)=1.32 [95%CI (1.10-1.59)]. In addition, there was evidence of association for the genotypic contrast PON1-55MM+LM relative to PON1-55LL: fixed effects OR=1.50 [95%CI (1.16-1.95)]. There was no significant association between PON1-192Q/R alleles and risk of developing PD: OR=1.09 [95%CI (0.93-1.26)]. There was no evidence for an association between the genotypic contrasts of PON1-192 and development of PD. The heterogeneity between studies and the publication bias were not significant ( P> or =0.10) in either polymorphism. Therefore, the pooled results of the meta-analysis supported that there was an association between PON1-55M/L polymorphism and PD and that PON1-192Q/R polymorphism was unlikely to be a major risk factor for susceptibility to PD.

Publication types

  • Comparative Study
  • Meta-Analysis

MeSH terms

  • Alleles*
  • Aryldialkylphosphatase / genetics*
  • Asian People / genetics
  • Case-Control Studies
  • Genetic Carrier Screening
  • Genetic Predisposition to Disease
  • Humans
  • Parkinson Disease / genetics*
  • Polymorphism, Genetic*
  • Risk Assessment
  • White People / genetics

Substances

  • Aryldialkylphosphatase